{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for folic root_modifications_structuralModifications_molecularFragment_refPname in root_modifications_structuralModifications_molecularFragment_refPname (approximate match)
Status:
US Approved Rx
(2023)
Source:
BLA761161
(2023)
Source URL:
First approved in 2023
Source:
BLA761161
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2023)
Source:
BLA761309
(2023)
Source URL:
First approved in 2023
Source:
BLA761309
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
NDA215866
(2022)
Source URL:
First approved in 2022
Source:
NDA215866
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761171
(2020)
Source URL:
First approved in 2020
Source:
BLA761171
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761172
(2020)
Source URL:
First approved in 2020
Source:
BLA761172
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
BLA761115
(2020)
Source URL:
First approved in 2020
Source:
BLA761115
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
NDA213182
(2020)
Source URL:
First approved in 2017
Source:
NDA209637
Source URL:
Class:
PROTEIN
Conditions:
Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. Semaglutide is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an acyl group with a steric diacid at Lys26 and a large synthetic spacer and modified by the presence of a α-aminobutyric acid in position 8 which gives stability against the dipeptidylpeptidase-4. Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1
receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.
The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which
results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is
stabilized against degradation by the DPP-4 enzyme.
Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers
glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is
stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor
delay in gastric emptying in the early postprandial phase.
Status:
US Approved Rx
(2017)
Source:
NDA208743
(2017)
Source URL:
First approved in 2017
Source:
NDA208743
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Abaloparatide (brand name Tymlos) is a human parathyroid hormone related peptide [PTHrP(1-34)]
analog indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a PTHrP(1-34) analog which acts as an agonist at the PTH1 receptor (PTH1R).
This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys,
abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone
mineral content (BMC) that correlated with increases in bone strength at vertebral and/or
nonvertebral sites. Abaloparatide was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Status:
US Approved Rx
(2017)
Source:
BLA761040
(2017)
Source URL:
First approved in 2017
Source:
BLA761040
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2015)
Source:
BLA125527
(2015)
Source URL:
First approved in 2014
Source:
BLA125554
Source URL:
Class:
PROTEIN